Literature DB >> 17504791

Ventilator-associated pneumonia due to colistin susceptible-only microorganisms.

F G Rios1, C M Luna, B Maskin, A Saenz Valiente, M Lloria, S Gando, C Sosa, S Baquero, C Llerena, C Petrati, C Apezteguia.   

Abstract

Acinetobacter spp. and Pseudomonas aeruginosa are common pathogens of ventilator-associated pneumonia (VAP). The presentation and outcome of VAP due to Acinetobacter spp. and P. aeruginosa susceptible to carbapenems (Carb-S; imipenem and/or meropenem) and to colistin only (Col-S) were compared in the present retrospective study in three intensive care units. A total of 61 episodes of VAP caused by Acinetobacter spp. or P. aeruginosa were studied, of which 30 isolates were Carb-S and 31 were Col-S. Demographics, worsening of renal function and mortality were not different. The univariate analysis showed that a later onset and a previous episode of VAP, prior antimicrobial therapy for >10 days and previous therapy with carbapenems during the present admission were more frequent in patients with Col-S strains. On multivariate analysis, prior antimicrobial therapy for >10 days and a previous episode of VAP remained significantly associated with Col-S VAP. Approximately 41% of the infections caused by Col-S isolates, but none of those due to Carb-S isolates, had received prior carbapenem therapy. Colistin-susceptible ventilator-associated pneumonia episodes can be effectively treated using colistin without significant renal dysfunction. This susceptibility pattern could be suspected in patients with a previous ventilator-associated pneumonia episode or prior antibiotic therapy for >10 days preceding the present ventilator-associated pneumonia episode.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17504791     DOI: 10.1183/09031936.00156906

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  18 in total

1.  [How often is bronchopneumonia overlooked as the cause of death in intensive care unit patients?].

Authors:  S Koch; J Bredahl; S P Wirtz; U R Jahn; S Gunia
Journal:  Anaesthesist       Date:  2008-01       Impact factor: 1.041

Review 2.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

3.  Defining, treating and preventing hospital acquired pneumonia: European perspective.

Authors:  Antoni Torres; Santiago Ewig; Harmut Lode; Jean Carlet
Journal:  Intensive Care Med       Date:  2008-11-07       Impact factor: 17.440

4.  [Colistin : renaissance of an old antibiotic?].

Authors:  H Stocker; W V Kern
Journal:  Internist (Berl)       Date:  2013-08       Impact factor: 0.743

5.  Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients.

Authors:  Marcelo M Mostardeiro; Carlos A P Pereira; Alexandre R Marra; Jose O M Pestana; Luis Fernando A Camargo
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

6.  When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock.

Authors:  Håkan Hanberger; Christian G Giske; Helen Giamarellou
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

Review 7.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

8.  Variables determining the development of colistin-associated renal impairment.

Authors:  Bahadır Ceylan; Müdür Taniş; Muhammed Emin Akkoyunlu; Ahmet Çınar; Ayşe Ruhkar Kurt; Yasemin Akkoyunlu; Didem Ozkan; Hatice Kutbay Ozcelik; Turan Aslan; Muzaffer Fincancı; Şule Vatansever; Kadir İdin; Emine Guler; Harun Uysal
Journal:  Wien Klin Wochenschr       Date:  2015-04-28       Impact factor: 1.704

9.  Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality.

Authors:  C Peña; S Gómez-Zorrilla; I Oriol; F Tubau; M A Dominguez; M Pujol; J Ariza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-24       Impact factor: 3.267

Review 10.  Multidrug-resistant Gram-negative infections: what are the treatment options?

Authors:  Helen Giamarellou; Garyphallia Poulakou
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.